Goldman Sachs Group Inc Acelrx Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

  • $580 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 14, 2024
BUY
$0.2 - $0.35 $12,371 - $21,649
61,855 New
61,855 $13,000
Q3 2022

Nov 10, 2022
BUY
$0.2 - $0.35 $12,371 - $21,649
61,855 New
61,855 $0
Q1 2022

May 16, 2022
SELL
$0.28 - $0.61 $20,267 - $44,154
-72,384 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$0.49 - $1.02 $11,622 - $24,193
23,719 Added 48.74%
72,384 $41,000
Q3 2021

Nov 10, 2021
BUY
$0.93 - $1.51 $45,258 - $73,484
48,665 New
48,665 $50,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email